Global, Regional, and National Burden of Ovarian Cancer Attributable to High Body-Mass Index Among Women Aged 55 Years and Older: A GBD 2021 Analysis [0.03%]
2021年全球、区域和国家层面上高体重指数所致≥55岁女性卵巢癌疾病负担:基于GBD 2021的分析
Jingfei Zheng,Hongfeng Li,Xuehe Li et al.
Jingfei Zheng et al.
Background: High body-mass index (BMI) defined in the Global Burden of Disease Study as BMI above the theoretical minimum risk exposure level, is an established modifiable risk factor for ovarian cancer, particularly amon...
Liquid Biopsy Biomarkers as Predictors of TNBC Recurrence: A Systematic Review [0.03%]
循环生物标志物在三阴性乳腺癌复发预测中的作用:系统综述
Nur Rahadiani,Dyah Laksmi Dewi,Mohammad Ghozali
Nur Rahadiani
Introduction: Triple-negative breast cancer (TNBC) is associated with high recurrence and mortality. Liquid biopsy biomarkers, such as circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), and microRNAs (miRNAs), offer no...
Yuqi Sheng,Yuwei Yang,Ruizhe Zhang et al.
Yuqi Sheng et al.
Spatial transcriptomics (ST) is revolutionizing pan-cancer analysis by enabling the in situ integration of spatial architecture with molecular profiles. This review synthesizes key advances, including deciphering conserved and divergent spa...
Quantifying the Mediation Effect of Disease Stage on Racial Disparities in Head and Neck Cancer Survival [0.03%]
量化疾病阶段在头颈癌生存率种族差异中的中介作用
Uchechukwu C Megwalu,Yifei Ma
Uchechukwu C Megwalu
There are significant racial and ethnic disparities in head and neck cancer (HNC) survival. Disparities in cancer stage appear to account for some of the disparities in survival. However, the proportion of the survival disparities mediated ...
Efficacy and Safety of Pembrolizumab in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis [0.03%]
帕博利珠单抗治疗晚期胃癌的疗效和安全性:系统评价和meta分析
Kunhong Tang,Wei Zheng Huang,Jiaqi Wei et al.
Kunhong Tang et al.
This meta-analysis integrates data from 7 randomized controlled trials comprising 4,560 patients with advanced gastric cancer to evaluate the efficacy and safety of pembrolizumab as monotherapy or in combination with chemotherapy. Compared ...
Six Years Since Selinexor Approval for Relapsed Multiple Myeloma: What Have We Learned? [0.03%]
选择性批准复发多发性骨髓瘤六年了,我们学到了什么?
Samer Al Hadidi,Rajshekhar Chakraborty,Ghulam Rehman Mohyuddin
Samer Al Hadidi
Prognostic Value of miR-145 in HER2-Positive Locally Advanced or Metastatic Urothelial Carcinoma Treated with Disitamab Vedotin [0.03%]
miR-145在HER2阳性局部晚期或转移性尿路上皮癌迪塞替尼治疗中的预后价值
Binghai Li,Dan Li,Ningning Deng et al.
Binghai Li et al.
Disitamab vedotin (RC48), a HER2-targeted antibody-drug conjugate, has shown promising activity in locally advanced or metastatic urothelial carcinoma (la/mUC), but clinically useful biomarkers remain lacking. In this retrospective single-c...
Studying the Relations of Behavioral Inhibition and Activation System Sensitivities and Time Perspective Orientations with Skin Cancer Screening Behaviors in Older Adults: Do Skin Cancer Screening Perceptions Mediate These Relations? [0.03%]
行为抑制激活系统敏感度和时间观取向与老年人皮肤癌筛查行为关系研究:皮肤癌筛查感知的中介作用?
Matt C Howard
Matt C Howard
To advance current research on skin cancer screening perceptions and behaviors, we investigate two distinct but related theoretical perspectives: (1) the behavioral inhibition and activation system and (2) time perspective orientations. Uti...
Mutational and Expressional Deregulation of the CHEK1 Gene in Breast Cancer Patients [0.03%]
乳腺癌患者中CHEK1基因的突变和表达异常
Azhar Mehmood,Ishrat Mahjabeen,Asif Nisar et al.
Azhar Mehmood et al.
Background: Breast cancer burden is increasing day by day. The identification of novel genetic markers based on polymorphism and expression analysis is necessary to reduce the suffering of patients. ...
Sex-Specific Adverse Events and Cardiovascular Toxicity of Cabozantinib in Renal Cell Carcinoma: A Nine-Year Pharmacovigilance Study [0.03%]
卡博替尼治疗肾细胞癌的性别差异不良反应和心血管毒性的九年的药物警戒研究
Erhao Bao,Yuchen Li,Yang Yang et al.
Erhao Bao et al.
Background: Cabozantinib is a multi-target tyrosine kinase inhibitor widely used in advanced renal cell carcinoma (RCC). However, real-world evidence regarding its safety profile, particularly sex-specific adverse events ...